You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR PSEUDOEPHEDRINE SULFATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Pseudoephedrine Sulfate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00837915 ↗ Bioequivalnce Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fasting Conditions Completed Ranbaxy Laboratories Limited N/A 2002-06-01 The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Schering (Claritin-D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets, in a fully replicated design, under fasting conditions.
NCT00845546 ↗ Bioequivalence Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fed Conditions Completed Ranbaxy Laboratories Limited N/A 2002-06-01 The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Schering (Claritin-D® 24 hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets, in a fully replicated design, under fed conditions.
NCT01055756 ↗ Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis Withdrawn Azidus Brasil Phase 3 2010-01-01 The primary objective of this study is to evaluate the clinical efficacy of the drug Cloratadd D ® (loratadine + pseudoephedrine sulfate - EMS S/A) compared to the drug Claritin D ® (loratadine + pseudoephedrine sulfate - Schering Plough) in patients with allergic rhinitis by quantification of the scores of clinical parameters (signs and symptoms) and laboratory (nasal flow) down through time.
NCT01293201 ↗ Trial of STAHIST in Seasonal Allergic Rhinitis Completed Magna Pharmaceuticals, Inc. Phase 3 2011-03-01 The overall development plan is to show that the combination of tried-and-proven decongestant/antihistamine ingredients (pseudoephedrine hydrochloride and chlorpheniramine maleate), plus a very small amount of belladonna alkaloids (.24 mg atropine sulfate) is a comprehensive, safe and effective B.I.D. drug treatment regimen, indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. Treated symptoms include nasal congestion, sneezing, rhinorrhea, itchy nose, itchy/watery eyes, and post nasal drip syndrome [reduction in tickly cough (acute or chronic), mucus in the back of the throat, sore throat, and hoarseness]. Considering the favorable safety and efficacy results of Phase 1 and Phase 2, the purpose of Phase 3 is to assess and compare the safety and efficacy of the study drug in a larger group comparatively with a placebo control group. Objectives: A) To report and compare total symptom scores (TSS) by SAR subjects rating the efficacy of STAHIST vs. placebo in relieving nasal congestion, rhinorrhea, nasal itching, sneezing, and post-nasal drip over the two-week study period. B) Report any side effects or adverse drug reactions and rate the severity of any incident. C) Compare and report each symptom score, total nasal symptom scores (TNSS), and post-nasal drip symptom scores (PND-S) between the two study arms.
NCT01373138 ↗ Bioequivalence Study of Desloratadine and Pseudoephedrine Sulfate Extended-release Tablets Under Fasting Conditions Completed Dr. Reddy's Laboratories Limited Phase 1 2006-04-01 This is an open label randomised, 2-way crossover, comparative bioequivalence study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pseudoephedrine Sulfate

Condition Name

Condition Name for Pseudoephedrine Sulfate
Intervention Trials
Healthy 3
Clinical Pharmacology 2
Seasonal Allergic Rhinitis 1
Allergic Rhinitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pseudoephedrine Sulfate
Intervention Trials
Rhinitis, Allergic 3
Rhinitis 3
Malnutrition 2
Rhinitis, Allergic, Seasonal 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pseudoephedrine Sulfate

Trials by Country

Trials by Country for Pseudoephedrine Sulfate
Location Trials
United States 8
Canada 4
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pseudoephedrine Sulfate
Location Trials
New Jersey 2
Ohio 1
Kentucky 1
Indiana 1
Georgia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pseudoephedrine Sulfate

Clinical Trial Phase

Clinical Trial Phase for Pseudoephedrine Sulfate
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 1 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pseudoephedrine Sulfate
Clinical Trial Phase Trials
Completed 7
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pseudoephedrine Sulfate

Sponsor Name

Sponsor Name for Pseudoephedrine Sulfate
Sponsor Trials
Bayer 3
Ranbaxy Laboratories Limited 2
Azidus Brasil 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pseudoephedrine Sulfate
Sponsor Trials
Industry 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.